Factor IX Deficiency (Hemophilia B) Guidelines

Updated: Nov 29, 2022
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Srikanth Nagalla, MD, MS, FACP  more...
  • Print

Guidelines Summary

Medical advances, including use of recombinant factor IX (FIX) and extended half-life FIX, have markedly improved the care of patients with hemophilia B. .However, because the disease is relatively rare, only limited published evidence and clinical experience are available for establishing clinical guidelines. Consequently, an international group of hematology experts has developed consensus recommendations on the clinical management of hemophilia B. [39] The group has proposed 29 recommendations that cover the following five topics:

  • Factor treatment choice
  • Therapeutic agent laboratory monitoring
  • Pharmacokinetics considerations
  • Inhibitor management
  • Preparing for gene therapy

For more information, see Hemophilia B.